NA
HUMA icon

NewEdge Advisors’s Humacyte HUMA Stock Holding History

NewEdge Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39 Hold
50
– – ﹤0.01% 4157
2026
Q1 		$30 Hold
50
– – ﹤0.01% 4104
2025
Q4 		$48 Hold
50
– – ﹤0.01% 4171
2025
Q3 		$87 Hold
50
– – ﹤0.01% 4038
2025
Q2 		$105 Hold
50
– – ﹤0.01% 3902
2025
Q1 		$85 Hold
50
– – ﹤0.01% 3832
2024
Q4 		$253 Hold
50
– – ﹤0.01% 3729
2024
Q3 		$272 Buy
+50
New +$330 ﹤0.01% 3663

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NewEdge Advisors's HUMA Position: Q2 2026 in Review

NewEdge Advisors held its Humacyte (HUMA) position steady in Q2 2026 at 50 shares worth $39. The position accounts for ﹤0.01% of the portfolio, ranked #4157.

NewEdge Advisors first reported a position in HUMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $272 in Q3 2024. 110 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • NewEdge Advisors held 50 shares of Humacyte worth $39 as of Q2 2026.
  • NewEdge Advisors left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4157 holding.
  • NewEdge Advisors first reported a position in Humacyte in Q3 2024 and has held it in 8 quarters since.
  • NewEdge Advisors's Humacyte position peaked at $272 in Q3 2024.
  • 110 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.